Hydrogen sulfide promotes proliferation and neuronal differentiation of neural stem cells and protects hypoxia-induced decrease in hippocampal neurogenesis.

Pharmacol Biochem Behav

Key Laboratory of the Ministry of Education for Experimental Teratology, Shandong Provincial Key Laboratory of Mental Disorders, Department of Histology and Embryology, Shandong University School of Medicine, 44#, Wenhua Xi Road, Jinan, Shandong 250012, PR China. Electronic address:

Published: January 2014

Accumulating evidence has suggested that hydrogen sulfide (H2S) acts as a novel neuro-modulator and neuroprotective agent; however, it remains to be investigated whether H2S has a direct effect on neural stem cells (NSCs). In the present study, we examined the effects of H2S donor, sodium hydrosulfide (NaHS) on mouse NSCs and hippocampal neurogenesis. We report here that NaHS promoted proliferation and neuronal differentiation of NSCs. Further analysis revealed that NaHS-induced proliferation was associated with phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and neuronal differentiation was linked to altered expression of differentiation-related genes. In addition, C57BL/6 mice (1 day old) subjected to hypoxia were treated with NaHS to explore whether H2S would influence the neurogenesis of hippocampus. BrdU incorporation assay results showed that administration of NaHS could increase the number of proliferating cells in the dentate gyrus of hippocampus in the mice after hypoxia. Moreover, Morris water maze test showed that treatment with NaHS improved cognitive impairment after hypoxia in mice. These findings suggest that H2S may afford a novel therapeutic strategy to intervene in the progression of brain diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pbb.2013.11.009DOI Listing

Publication Analysis

Top Keywords

neuronal differentiation
12
hydrogen sulfide
8
proliferation neuronal
8
neural stem
8
stem cells
8
hippocampal neurogenesis
8
h2s
5
nahs
5
sulfide promotes
4
promotes proliferation
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Aptah Bio Inc., San Carlos, CA, USA.

Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Retromer Therapeutics, New York, NY, USA.

Background: Convergent evidence indicates that deficits in the endosomal recycling pathway underlies pathogenesis of Alzheimer's disease (AD). SORL1 encodes the retromer-associated receptor SORLA that plays an essential role in recycling of AD-associated cargos such as the amyloid precursor protein and the glutamatergic AMPA receptor. Importantly, loss of function pathogenic SORL1 variants are associated with AD.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is the most prevalent cause of dementia accounting for an estimated 60% to 80% of cases. Despite advances in the research field, developing truly effective therapies for AD symptoms remains a major challenge. Sweet almond contain nutrients that have the potential of combating age-related brain dysfunction, by improving learning, memory and neurocognitive performance.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Beckman Research Institute of City of Hope, Duarte, CA, USA.

Background: Brain organoid models were generated from healthy control or Alzheimer's disease patient iPSCs to facilitate our understanding of AD pathogenesis.

Method: ApoE3 and ApoE4 iPSCs were developed into brain organoids using our recently developed brain organoid platform that allows prolonged culture of brain organoids. Human iPSCs were also differentiated into microglia, which were then co-cultured with brain organoids.

View Article and Find Full Text PDF

Background: Efforts to genetically reverse C9orf72 pathology have been hampered by our incomplete understanding of the regulation of this complex locus.

Method: We generated five different genomic excisions at the C9orf72 locus in a patient-derived iPSC line and a WT line (11 total isogenic lines), and examined gene expression and pathological hallmarks of C9 FTD/ALS in motor neurons differentiated from these lines. Comparing the excisions in these isogenic series removed the confounding effects of different genomic backgrounds and allowed us to probe the effects of specific genomic changes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!